Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease.

A Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group Study To Evaluate the Efficacy And Safety of UK-432,097 Dry Powder For Inhalation In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease.

Safety and efficacy (measured by spirometry) of UK-432,097 administration will be tested in patients with chronic obstructive pulmonary disease.

Inclusion Criteria:

• Patients with a diagnosis, for at least 6 months, of moderate to severe COPD (GOLD) and who meet the criteria for Stage II-III disease
• Patients must have a smoking history of at least 10 pack-years
• Patients must have stable disease for at least 1 month prior to screening.

Exclusion Criteria:

• More than 2 exacerbations of COPD in the preceding year
• History of a lower respiratory tract infection or significant disease instability during the month proceding screening or during the time between screen and randomization.
• History or presence of respiratory failure, cor pulmonale or right ventricular failure